Randomized, Placebo-Controlled Trial of N-acetylcysteine In Parkinson's Disease Patients: A Pilot… (NCT07093944) | Clinical Trial Compass
CompletedPhase 2
Randomized, Placebo-Controlled Trial of N-acetylcysteine In Parkinson's Disease Patients: A Pilot Study
Iran42 participantsStarted 2018-04-09
Plain-language summary
This is a study on Parkinson's disease patients, referred to Tohid Hospital of Sanandaj City. The patients receive N-acetylcysteine for one year. The efficacy of the Drug is evaluated based on clinical interview, filling Unified Parkinson's Disease Rating Scale (UPDRS) questionnaire, and single-photon emission computerized tomography (SPECT) brain imaging. The only person who has not been blinded for the study is the supplier of the drug and placebo.
Inclusion criteria: Patient's informed consent Exclusion criteria: Having brain surgery within a year before the initiation of the intervention.
Medication group: receiving 1200 mg N-acetylcysteine per day, twice daily, each time 600 mg.
placebo group: receiving a placebo with similar appearance, color, odor, and taste like real medication.
Who can participate
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patient's informed consent No brain surgery in the patient's post medical history
Exclusion Criteria:
* having brain surgery within a year before starting the treatment period
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial tested N-acetylcysteine, which is already available as a supplement, so how does the evidence from this Phase 2 pilot study compare to just taking it on my own, and would you recommend waiting for larger trials before considering it?
2The trial measured dopamine transporter changes using SPECT brain imaging — do you think my current imaging results would make me a good or poor candidate for a treatment like this, based on what this study found?
3Since this was a pilot study, meaning it was designed mainly to test feasibility and early signals rather than prove effectiveness, how much weight should I put on its results when thinking about my own treatment plan?
4The trial also tracked UPDRS scores, which measure how Parkinson's affects movement and daily life — did the results suggest any meaningful change in those real-world symptoms, or mainly in the brain imaging data?
5Given that this trial is already completed, are there follow-up studies planned that might be more relevant for me to consider joining, or does the data from this pilot change anything about the standard-of-care options you'd recommend for me right now?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.